Steve Schonfeld’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $9.37M | Sell |
31,112
-40,655
| -57% | -$12.3M | 0.03% | 434 |
|
|
2026
Q1 | $23.7M | Buy |
71,767
+26,873
| +60% | +$9.14M | 0.17% | 120 |
|
|
2025
Q4 | $17.9M | Buy |
44,894
+35,185
| +362% | +$15.6M | 0.08% | 222 |
|
|
2025
Q3 | $4.43M | Sell |
9,709
-49,048
| -83% | -$20M | 0.03% | 639 |
|
|
2025
Q2 | $19.2M | Buy |
58,757
+55,675
| +1,806% | +$15.4M | 0.13% | 168 |
|
|
2025
Q1 | $832K | Sell |
3,082
-123,918
| -98% | -$31.8M | 0.01% | 1361 |
|
|
2024
Q4 | $29.9M | Buy |
127,000
+99,133
| +356% | +$26.1M | 0.17% | 94 |
|
|
2024
Q3 | $7.66M | Sell |
27,867
-16,108
| -37% | -$4.19M | 0.05% | 380 |
|
|
2024
Q2 | $10.7M | Sell |
43,975
-191,631
| -81% | -$30.3M | 0.07% | 329 |
|
|
2024
Q1 | $35.2M | Buy |
235,606
+233,653
| +11,964% | +$39M | 0.23% | 72 |
|
|
2023
Q4 | $374K | Sell |
1,953
-40,154
| -95% | -$6.84M | ﹤0.01% | 1370 |
|
|
2023
Q3 | $7.46M | Buy |
42,107
+39,641
| +1,608% | +$7.56M | 0.06% | 437 |
|
|
2023
Q2 | $468K | Sell |
2,466
-12,770
| -84% | -$2.53M | ﹤0.01% | 1246 |
|
|
2023
Q1 | $3.05M | Buy |
+15,236
| New | +$3.2M | 0.03% | 583 |
|
|
2022
Q4 | – | Sell |
-33,615
| Closed | -$6.73M | – | 2557 |
|
|
2022
Q3 | $6.73M | Buy |
+33,615
| New | +$6.41M | 0.06% | 432 |
|
|
2022
Q2 | – | Sell |
-6,700
| Closed | -$1.09M | – | 2495 |
|
|
2022
Q1 | $1.09M | Buy |
+6,700
| New | +$1.02M | 0.01% | 944 |
|
|
2021
Q3 | – | Sell |
-18,968
| Closed | -$3.22M | – | 2128 |
|
|
2021
Q2 | $3.22M | Buy |
18,968
+10,868
| +134% | +$1.59M | 0.03% | 572 |
|
|
2021
Q1 | $1.14M | Buy |
+8,100
| New | +$1.22M | 0.01% | 840 |
|
|
2019
Q3 | – | Sell |
-73,600
| Closed | -$5.34M | – | 1005 |
|
|
2019
Q2 | $5.34M | Buy |
73,600
+10,900
| +17% | +$836K | 0.19% | 133 |
|
|
2019
Q1 | $5.86M | Buy |
62,700
+47,700
| +318% | +$3.99M | 0.2% | 133 |
|
|
2018
Q4 | $1.09M | Sell |
15,000
-51,500
| -77% | -$3.96M | 0.04% | 460 |
|
|
2018
Q3 | $5.82M | Hold |
66,500
| – | – | 0.26% | 111 |
|
|
2018
Q2 | $6.55M | Buy |
66,500
+51,500
| +343% | +$5.11M | 0.36% | 78 |
|
|
2018
Q1 | $1.79M | Sell |
15,000
-3,575
| -19% | -$461K | 0.13% | 218 |
|
|
2017
Q4 | $2.36M | Buy |
+18,575
| New | +$2.33M | 0.19% | 147 |
|
|
2016
Q4 | – | Sell |
-25,618
| Closed | -$1.74M | – | 536 |
|
|
2016
Q3 | $1.74M | Buy |
+25,618
| New | +$1.81M | 0.3% | 86 |
|
Other funds holding ALNY
Steve Schonfeld's ALNY Position: Q2 2026 in Review
Steve Schonfeld reduced its Alnylam Pharmaceuticals (ALNY) stake by 57% in Q2 2026, selling an estimated $12.3M and leaving 31,112 shares worth $9.37M. The position accounts for 0.03% of the portfolio, ranked #434.
Steve Schonfeld first reported a position in ALNY in Q3 2016 and has held it in 26 quarters since. The position peaked at $35.2M in Q1 2024. 784 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.
- Steve Schonfeld held 31,112 shares of Alnylam Pharmaceuticals worth $9.37M as of Q2 2026.
- Steve Schonfeld sold 40,655 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $12.3M.
- Alnylam Pharmaceuticals made up 0.03% of Steve Schonfeld's portfolio in Q2 2026, its #434 holding.
- Steve Schonfeld first reported a position in Alnylam Pharmaceuticals in Q3 2016 and has held it in 26 quarters since.
- Steve Schonfeld's Alnylam Pharmaceuticals position peaked at $35.2M in Q1 2024.
- 784 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.
Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.